lyophilization is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
platelet-derived growth factor transforming growth factor beta fibroblast growth factor insulin-like growth factor 1 insulin-like growth factor 2 vascular endothelial growth factor A vascular endothelial growth factor C epidermal growth factor interleukin 8 keratinocyte growth factor connective tissue growth factor hepatocyte growth factor stromal cell-derived factor 1 endostatin
== Death == On February 21, 1961, Jones died of lung cancer at age 67 in Minneapolis, Minnesota, predeceasing his wife, Lucille. In an obituary in the Saturday Evening Post, it was said, "Most engineers start at the bottom of a project and work up, but Fred takes a flying leap to the top of the mountain and then backs down, cutting steps for himself and the rest of us as he goes." Jones continued filing for patents almost up until his death, receiving his last patent in February 1960.
He served as an Automatic Tracking Radar repairman, rising to the rank of airman first class. After serving from 1955 to 1959, he moved to Los Angeles and took acting classes at the Pasadena Playhouse. He also studied theater arts at Los Angeles City College, where a teacher encouraged him to embark on a dance career.
==== Wound dressings ==== Chitosan-containing wound dressings have been widely explored for a variety of acute and chronic wounds. Chitosan is used within some wound dressings to decrease bleeding. Upon contact with blood, the bandage becomes sticky, effectively sealing the laceration. There are many ways to incorporate chitosan into wound dressings:
=== Hydroxykynureninuria === Also known as kynureninase deficiency, this extremely rare inherited disorder is caused by the defective enzyme kynureninase which leads to a block in the pathway from tryptophan to nicotinic acid mononucleotide (NaMN). As a result, tryptophan is no longer a source of niacin, hence not producing NAD, leading to pellagra (niacin deficiency). Both B6-responsive and B6-unresponsive forms are known. Patients with this disorder excrete excessive amounts of xanthurenic acid, kynurenic acid, 3-hydroxykynurenine, and kynurenine after tryptophan loading and are said to suffer from tachycardia, irregular breathing, arterial hypotension, cerebellar ataxia, developmental retardation, coma, renal tubular dysfunction, renal or metabolic acidosis, and even death. The only biochemical abnormality noted in affected patients was a massive hyperkynureninuria, seen only during periods of coma or after intravenous protein loading. This disturbance was temporarily corrected by large doses of vitamin B6. The activity of kynureninase in the liver was markedly reduced. The activity was appreciably restored by the addition of pyridoxal phosphate.
Sources: en.wikipedia.org
The Transitional Federal Government (TFG) was the internationally recognised government of Somalia until 20 August 2012, when its tenure officially ended. It was established as one of the Transitional Federal Institutions (TFIs) of government as defined in the Transitional Federal Charter (TFC) adopted in November 2004 by the Transitional Federal Parliament (TFP). The Transitional Federal Government officially comprised the executive branch of government, with the TFP serving as the legislative branch. The government was headed by the President of Somalia, to whom the cabinet reported through the Prime Minister. However, it was also used as a general term to refer to all three branches collectively. Owing to a lack of funding and human resources, an arms embargo that made it difficult to reestablish a national security force, and general indifference on the part of the international community, Yusuf found himself obliged to deploy thousands of troops from Puntland to Mogadishu to sustain the battle against insurgent elements in the southern part of the country. Financial support for this effort was provided by the autonomous region's government. This left little revenue for Puntland's own security forces and civil service employees, leaving the territory vulnerable to piracy and terrorist attacks. On 29 December 2008, Yusuf announced before a united parliament in Baidoa his resignation as President of Somalia.
=== 1934: Porcelain Steel Buildings subsidiary === White Castle also created a subsidiary in 1934 named Porcelain Steel Buildings that manufactured movable, prefabricated, steel frame structures with porcelain enamel interior and exterior panels that could be assembled at any of its restaurant sites. This is the first known use of this material in a building design.
== Later research == Later research projects conducted by Leeman and her lab were centered around the two peptides, substance P and neurotensin, that she originally isolated, sequenced, and synthesized. Her lab at Boston University has multiple goals regarding these neural peptides, including mapping their distribution within the brain and peripheral nervous system, delineating tracts containing substance P or neurotensin within the central nervous system, determining how substance P and neurotensin are released from neural tissue in vitro and in vivo, and identifying the binding domain of substance P with its receptor.
== Physical and chemical properties == In its isolated or synthesized form, the active compound appears as an amorphous white solid, and elemental analysis shows that it consists of 70.56% carbon, 8.07% hydrogen, and 21.36% oxygen. The distinctive chemical feature of Guanacastepene A stems from the so-called guanacastane skeleton.
== Treatment == Only a small proportion of those with co-occurring disorders actually receive treatment for both disorders. Therefore, it was argued that a new approach is needed to enable clinicians, researchers and managers to offer adequate assessment and evidence-based treatments to patients with dual pathology, who cannot be adequately and efficiently managed by cross-referral between psychiatric and addiction services as currently configured and resourced. In 2011, it was estimated that only 12.4% of American adults with co-occurring disorders were receiving both mental health and addictions treatment. Clients with co-occurring disorders face challenges accessing treatment, as they may be excluded from mental health services if they admit to a substance use problem and vice versa. There are multiple approaches to treat concurrent disorders. Partial treatment involves treating only the disorder that is considered primary. Sequential treatment involves treating the primary disorder first, and then treating the secondary disorder after the primary disorder has been stabilized. Parallel treatment involves the client receiving mental health services from one provider, and addictions services from another. Integrated treatment involves a seamless blending of interventions into a single coherent treatment package developed with a consistent philosophy and approach among care providers. With this approach, both disorders are considered primary.
Sources: en.wikipedia.org
=== Hospitals === Most clinical teaching takes place in facilities operated by UNC Health, primarily within the UNC Medical Center complex at the southern tip of the UNC campus. The complex comprises five healthcare facilities collectively known as UNC Hospitals, including North Carolina Memorial Hospital, North Carolina Children’s Hospital, North Carolina Women’s Hospital, North Carolina Neurosciences Hospital, and North Carolina Cancer Hospital. In 2024, the North Carolina Surgical Hospital was opened, featuring 26 new surgical spaces and 80 inpatient rooms. Together, these facilities offer over 1,000 inpatient beds and are ranked as the 2nd best hospital in the state of North Carolina. Additional hospitals and outpatient clinics in the area are also used for training, including the Ambulatory Care Center, the Family Medicine Building, UNC Hillsborough, and UNC Chatham. During the Application Phase (third year) of the school's MD program, students will be matched into one of six regions located across the state of North Carolina to complete their clinical clerkships at local facilities, including:
=== Speech and sound creation === Sound synthesis, various methods of sound generation in audio electronics Wave field synthesis, a spatial audio rendering technique, characterized by creation of virtual acoustic environments Subtractive synthesis, a method of creating a sound by removing harmonics, characterised by the application of an audio filter to an audio signal Frequency modulation synthesis, a form of audio synthesis where the timbre of a simple waveform is changed by frequency modulating it with a modulating frequency that is also in the audio range Speech synthesis, the artificial production of human speech
== Side effects == Possible and rare side effects may include dizziness, hypotension, indigestion, allergic reactions (itchy skin) after high doses, hypothermia, fatigue. And lowered blood pressure and/or body temperature decreased by 1 to 1.5 °C. Blood pressure and body temperature return to normal after completion of treatment.
=== Mauritius === Mauritius is dependent on oil imports for generating power, and, after a shipment of oil had not arrived as scheduled on 30 March, only 21 days of stock remained in the country. The government arranged for more expensive alternative fuel to be shipped from Singapore, and imposed restrictions to reduce wastage of fuel.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.